J. Mark FitzGerald

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.3K citations

Asthma, Rheumatology, Placebo-controlled Phase 3 +9

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez et al. · The Lancet · 2016 · 1.3K citations

Asthma, Allergy, Placebo-controlled Phase 3 +10

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies

J. Mark FitzGerald, Eugene R. Bleecker, Andrew Menzies‐Gow et al. · The Lancet Respiratory Medicine · 2017 · 309 citations

Asthma, Rheumatology, Allergy +8

Antibiotic Use in Children Is Associated With Increased Risk of Asthma

Fawziah Marra, Carlo A. Marra, Kathryn Richardson et al. · PEDIATRICS · 2009 · 281 citations

Bronchial Thermoplasty for Asthma

Gerard Cox, John D. Miller, Annette McWilliams et al. · American Journal of Respiratory and Critical Care Medicine · 2006 · 278 citations